Disease modification in Parkinson’s disease: are we there yet with currently available therapies?

SUMMARY Management of Parkinson’s disease (PD) is currently based primarily on dopamine-replacement therapy for the alleviation of motor symptoms. Current medical and surgical therapies can provide long-lasting symptomatic benefit, but they do not modify progression of the disease. Research is ongoing to find a therapy that can provide neuroprotection, defined herein as preventing vulnerable neurons from dying. Studies of neuroprotection are limited by a lack of adequate biomarkers of PD progression and by the confounding symptomatic effects of many putative neuroprotective therapies. Studies have shown that levodopa prolongs life, but they have not clearly shown that it modifies disease progression. Trials of dopamine agonists have demonstrated symptomatic effect but no unequivocal neuroprotective benefits. While some studies of monamine oxidase B inhibitors have been promising, they have not conclusively proven disease modification. Exercise provides many benefits to patients with PD, may modify the pro...

[1]  P. Auinger,et al.  Activity enhances dopaminergic long-duration response in Parkinson disease , 2012, Neurology.

[2]  Elizabeth Eckstrom,et al.  Tai chi and postural stability in patients with Parkinson's disease. , 2012, The New England journal of medicine.

[3]  A. Singleton,et al.  The Parkinson Progression Marker Initiative (PPMI) , 2011, Progress in Neurobiology.

[4]  David J. Brooks,et al.  Imaging biomarkers in Parkinson's disease , 2011, Progress in Neurobiology.

[5]  D. Hurley FDA Committee: Rasagiline Rejected as ‘Disease Modifying’ for Parkinson Disease , 2011 .

[6]  M. Herrero,et al.  Neuroprotective Role of Dopamine Agonists: Evidence From Animal Models and Clinical Studies , 2011, The neurologist.

[7]  T. Révész,et al.  Does levodopa accelerate the pathologic process in Parkinson disease brain? , 2011, Neurology.

[8]  K. Lyons,et al.  The impact and management of nonmotor symptoms of Parkinson's disease. , 2011, The American journal of managed care.

[9]  J. Nutt,et al.  The long-duration response to levodopa: phenomenology, potential mechanisms and clinical implications. , 2011, Parkinsonism & related disorders.

[10]  Lama M Chahine,et al.  Diagnostic markers for Parkinson's disease. , 2011, Current opinion in neurology.

[11]  W. Severt,et al.  Disease Modification in Parkinson’s Disease , 2011, Drugs & aging.

[12]  J. Ahlskog Does vigorous exercise have a neuroprotective effect in Parkinson disease? , 2011, Neurology.

[13]  B. Bloem,et al.  How might physical activity benefit patients with Parkinson disease? , 2011, Nature Reviews Neurology.

[14]  A. Brickman,et al.  Physical activity and Alzheimer disease course. , 2011, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[15]  R. Newton,et al.  Exercise and Parkinson’s: benefits for cognition and quality of life , 2011, Acta neurologica Scandinavica.

[16]  A. Espay Management of motor complications in Parkinson disease: current and emerging therapies. , 2010, Neurologic clinics.

[17]  C. Ballard,et al.  Neuroimaging for Lewy body disease: Is the in vivo molecular imaging of α-synuclein neuropathology required and feasible? , 2010, Brain Research Reviews.

[18]  W. Poewe,et al.  Rationale for delayed‐start study of pramipexole in Parkinson's disease: The PROUD study , 2010, Movement disorders : official journal of the Movement Disorder Society.

[19]  A. Schatzkin,et al.  Physical activities and future risk of Parkinson disease , 2010, Neurology.

[20]  V. Sossi,et al.  Trials of neuroprotective therapies for Parkinson's disease: problems and limitations. , 2010, Parkinsonism & related disorders.

[21]  K. Yaffe,et al.  Physical Activity Over the Life Course and Its Association with Cognitive Performance and Impairment in Old Age , 2010, Journal of the American Geriatrics Society.

[22]  Joe R. Nocera,et al.  Can exercise improve language and cognition in Parkinson's disease? A case report , 2010, Neurocase.

[23]  R. Uitti,et al.  Rasagiline, Parkinson neuroprotection, and delayed-start trials , 2010, Neurology.

[24]  Jeffrey N. Browndyke,et al.  Aerobic Exercise and Neurocognitive Performance: A Meta-Analytic Review of Randomized Controlled Trials , 2010, Psychosomatic medicine.

[25]  Werner Poewe,et al.  A double-blind, delayed-start trial of rasagiline in Parkinson's disease. , 2009, The New England journal of medicine.

[26]  W. Poewe,et al.  P1.203 Immediate vs. delayed-start pramipexole in early Parkinson's disease: the PROUD study , 2009 .

[27]  E. McAuley,et al.  Aerobic fitness is associated with hippocampal volume in elderly humans , 2009, Hippocampus.

[28]  G. Kwakkel,et al.  Is impact of fatigue an independent factor associated with physical activity in patients with idiopathic Parkinson's disease? , 2009, Movement disorders : official journal of the Movement Disorder Society.

[29]  W. Ondo,et al.  Long‐term outcome of early versus delayed rasagiline treatment in early Parkinson's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.

[30]  O. Rascol “Disease-modification” trials in Parkinson disease: Target populations, endpoints and study design , 2009, Neurology.

[31]  Monica Fabiani,et al.  Neuroanatomical correlates of aging, cardiopulmonary fitness level, and education. , 2008, Psychophysiology.

[32]  J. Gordon,et al.  The effect of exercise training in improving motor performance and corticomotor excitability in people with early Parkinson's disease. , 2008, Archives of physical medicine and rehabilitation.

[33]  Y-S Kwak,et al.  Effect of regular exercise on senile dementia patients. , 2008, International journal of sports medicine.

[34]  Orna Zagoory-Sharon,et al.  Oxytocin and cortisol in romantically unattached young adults: associations with bonding and psychological distress. , 2008, Psychophysiology.

[35]  Michael J Thun,et al.  Recreational physical activity and risk of Parkinson's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.

[36]  W. Weiner,et al.  Parkinson's Disease: Diagnosis and Clinical Management , 2007 .

[37]  T. Amit,et al.  Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro , 2007, Journal of neurochemistry.

[38]  James S. Williams,et al.  The effect of acute exercise on serum brain-derived neurotrophic factor levels and cognitive function. , 2007, Medicine and science in sports and exercise.

[39]  F. Gomez-Pinilla,et al.  Insulin-like growth factor I interfaces with brain-derived neurotrophic factor-mediated synaptic plasticity to modulate aspects of exercise-induced cognitive function , 2006, Neuroscience.

[40]  Paige E. Scalf,et al.  Aerobic exercise training increases brain volume in aging humans. , 2006, The journals of gerontology. Series A, Biological sciences and medical sciences.

[41]  A. Crizzle,et al.  Is Physical Exercise Beneficial for Persons with Parkinson's Disease? , 2006, Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine.

[42]  C. Cotman,et al.  Exercise primes a molecular memory for brain-derived neurotrophic factor protein induction in the rat hippocampus , 2005, Neuroscience.

[43]  Archana Singh-Manoux,et al.  Effects of physical activity on cognitive functioning in middle age: evidence from the Whitehall II prospective cohort study. , 2005, American journal of public health.

[44]  Fred H. Gage,et al.  Exercise Enhances Learning and Hippocampal Neurogenesis in Aged Mice , 2005, The Journal of Neuroscience.

[45]  B. Christie,et al.  Voluntary exercise alters the cytoarchitecture of the adult dentate gyrus by increasing cellular proliferation, dendritic complexity, and spine density , 2005, The Journal of comparative neurology.

[46]  Bente Klarlund Pedersen,et al.  The anti-inflammatory effect of exercise. , 2005, Journal of applied physiology.

[47]  H. Chen,et al.  Physical activity and the risk of Parkinson disease , 2005, Neurology.

[48]  C. Tanner,et al.  Levodopa and the progression of Parkinson's disease. , 2004, The New England journal of medicine.

[49]  G. Nappi,et al.  Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease , 2004, Experimental Neurology.

[50]  A. Baiker,et al.  VEGF is necessary for exercise‐induced adult hippocampal neurogenesis , 2003, The European journal of neuroscience.

[51]  K. Mohanakumar,et al.  D‐deprenyl protects nigrostriatal neurons against 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐induced dopaminergic neurotoxicity , 2003, Synapse.

[52]  Claude Nahmias,et al.  Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study , 2003, Annals of neurology.

[53]  Karl-Heinz Schulz,et al.  Basal serum levels and reactivity of nerve growth factor and brain-derived neurotrophic factor to standardized acute exercise in multiple sclerosis and controls , 2003, Journal of Neuroimmunology.

[54]  R. Albin,et al.  Initial agonist treatment of Parkinson disease , 2003, Neurology.

[55]  J. Jankovic,et al.  Slowing Parkinson’s disease progression , 2003, Neurology.

[56]  N. Cohen,et al.  Aerobic fitness reduces brain tissue loss in aging humans. , 2003, The journals of gerontology. Series A, Biological sciences and medical sciences.

[57]  J. Nutt,et al.  A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. , 2002, Archives of neurology.

[58]  C Stallibrass,et al.  Randomized controlled trial of the Alexander Technique for idiopathic Parkinson's disease , 2002, Clinical rehabilitation.

[59]  J. Penney,et al.  Impact of sustained deprenyl (selegiline) in levodopa‐treated Parkinson's disease: A randomized placebo‐controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial , 2002, Annals of neurology.

[60]  I. Torres-Aleman,et al.  Circulating Insulin-Like Growth Factor I Mediates the Protective Effects of Physical Exercise against Brain Insults of Different Etiology and Anatomy , 2001, The Journal of Neuroscience.

[61]  I. Torres-Aleman,et al.  Circulating Insulin-Like Growth Factor I Mediates Exercise-Induced Increases in the Number of New Neurons in the Adult Hippocampus , 2001, The Journal of Neuroscience.

[62]  J. Lindsay,et al.  Physical activity and risk of cognitive impairment and dementia in elderly persons. , 2001, Archives of neurology.

[63]  M. Murer,et al.  Brain-derived neurotrophic factor in the control human brain, and in Alzheimer’s disease and Parkinson’s disease , 2001, Progress in Neurobiology.

[64]  John Seibyl,et al.  Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. , 2000, JAMA.

[65]  T J Sejnowski,et al.  Running enhances neurogenesis, learning, and long-term potentiation in mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[66]  S Fahn,et al.  Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA. , 1999, Archives of neurology.

[67]  R. Palm,et al.  Selegiline delays the onset of disability in de novo parkinsonian patients , 1998, Neurology.

[68]  R. Uitti,et al.  Timely levodopa (LD) administration prolongs survival in Parkinson's disease. , 1997, Parkinsonism & related disorders.

[69]  A. J. Schwarz,et al.  Acute effect of brief low- and high-intensity exercise on circulating insulin-like growth factor (IGF) I, II, and IGF-binding protein-3 and its proteolysis in young healthy men. , 1996, The Journal of clinical endocrinology and metabolism.

[70]  C. Cotman,et al.  Physical activity increases mRNA for brain-derived neurotrophic factor and nerve growth factor in rat brain , 1996, Brain Research.

[71]  G. L. Curran,et al.  Permeability at the blood-brain and blood-nerve barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNF. , 1996, Brain research. Molecular brain research.

[72]  N. Volkow,et al.  Slow recovery of human brain MAO B after L‐Deprenyl (Selegeline) withdrawal , 1994, Synapse.

[73]  D. Maraganore,et al.  Levodopa therapy and survival in idiopathic Parkinson's disease , 1993, Neurology.

[74]  M. Brin,et al.  Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. , 1993, The New England journal of medicine.

[75]  K. Tatara,et al.  Effect of physical exercise on mortality in patients with Parkinson's disease , 1992, Acta neurologica Scandinavica.

[76]  C. Joseph,et al.  Levodopa in Parkinson disease: A long‐term appraisal of mortality , 1978, Annals of neurology.

[77]  R. Marttila,et al.  Mortality of patients with parkinson's disease treated with levodopa , 1977, Journal of Neurology.

[78]  F. Mcdowell,et al.  Five years' treatment of Parkinson's disease with levodopa. Therapeutic results and survival of 100 patients. , 1975, Annals of internal medicine.

[79]  M. Hallett,et al.  Principles and practice of movement disorders , 2011 .

[80]  C. Markham,et al.  Present mortality in Parkinson's disease: the ratio of observed to expected deaths with a method to calculate expected deaths , 2005, Journal of Neural Transmission.

[81]  S. Fahn Unified Parkinson's Disease Rating Scale , 1987 .

[82]  Hoehn Mm,et al.  Parkinson's disease: progression and mortality. , 1987 .

[83]  J. Siegfried,et al.  Mortality among Parkinson patients treated with L-dopa combined with a decarboxylase inhibitor. , 1976, European neurology.